Significance of anti-neutrophil cytoplasmic antibodies in systemic sclerosis

被引:31
作者
Moxey, Jayne [1 ,2 ]
Huq, Molla [1 ]
Proudman, Susanna [3 ,4 ]
Sahhar, Joanne [5 ,6 ]
Ngian, Gene-Siew [5 ,6 ]
Walker, Jenny [7 ]
Strickland, Gemma [8 ]
Wilson, Michelle [2 ]
Ross, Laura [1 ,2 ]
Major, Gabor [9 ,10 ]
Roddy, Janet [11 ]
Stevens, Wendy [2 ]
Nikpour, Mandana [1 ,2 ]
机构
[1] Univ Melbourne, 41 Victoria Parade Fitzroy, Melbourne, Vic 3065, Australia
[2] St Vincents Hosp Melbourne, 41 Victoria Parade Fitzroy, Melbourne, Vic 3065, Australia
[3] Univ Adelaide, Adelaide, SA, Australia
[4] Royal Adelaide Hosp, Adelaide, SA, Australia
[5] Monash Hlth, Melbourne, Vic, Australia
[6] Monash Univ, Melbourne, Vic, Australia
[7] Flinders Med Ctr, Adelaide, SA, Australia
[8] Barwon Rheumatol Serv, Geelong, Vic, Australia
[9] John Hunter Hosp, Royal Newcastle Ctr, Newcastle, NSW, Australia
[10] Univ Newcastle, Newcastle, NSW, Australia
[11] Fiona Stanley Hosp, Perth, WA, Australia
基金
英国医学研究理事会;
关键词
Anti-neutrophil cytoplasmic antibodies (ANCA); Systemic sclerosis (SSc); ANCA-associated vasculitis; Myeloperoxidase (MPO); Proteinase-3 (PR3); ANCA-ASSOCIATED VASCULITIS; RENAL-FAILURE; SCLERODERMA; AUTOANTIBODIES; MYELOPEROXIDASE; CLASSIFICATION; PATHOGENESIS;
D O I
10.1186/s13075-019-1839-5
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Up to 12% of patients with systemic sclerosis (SSc) have anti-neutrophil cytoplasmic antibodies (ANCA). However, the majority of these patients do not manifest ANCA-associated vasculitis (AAV) and the significance of ANCA in these patients is unclear. The aim of this study is to determine the prevalence of ANCA in a well-characterised SSc cohort and to examine the association between ANCA and SSc clinical characteristics, other autoantibodies, treatments and mortality. Clinical data were obtained from 5 centres in the Australian Scleroderma Cohort Study (ASCS). ANCA positive was defined as the presence of any one or combination of cytoplasmic ANCA (c-ANCA), perinuclear ANCA (p-ANCA), atypical ANCA, anti-myeloperoxidase (anti-MPO) or anti-proteinase-3 (anti-PR3). Associations of demographic and clinical features with ANCA were investigated by logistic or linear regression. Survival analysis was performed using Kaplan-Meyer curves and Cox regression models. Of 1303 patients, 116 (8.9%) were ANCA positive. Anti-PR3 was more common than anti-MPO (13.8% and 11.2% of ANCA-positive patients, respectively). Only 3 ANCA-positive patients had AAV. Anti-Scl-70 was more common in ANCA positive vs ANCA negative (25% vs 12.8%, p < 0.001), anti-MPO positive vs anti-MPO negative (38.5% vs 13.6%, p = 0.006) and anti-PR3 positive vs anti-PR3 negative patients (44.4% vs 13.4%, p < 0.001). A higher prevalence of interstitial lung disease (ILD) was found in the ANCA positive (44.8% vs 21.8%, p < 0.001) and the anti-PR3 positive groups (50.0% vs 23.4%, p = 0.009). In multivariable analysis, ANCA-positive status remained associated with ILD after adjusting for anti-Scl-70 antibodies. Pulmonary embolism (PE) was more common in ANCA-positive patients (8.6% vs 3.0%, p = 0.002) and anti-PR3-positive patients (16.7% vs 3.3%, p = 0.022). ANCA-positive status remained associated with PE in a multivariable analysis adjusting for anti-phospholipid antibodies. Kaplan-Meier analysis revealed increased mortality in ANCA-positive patients (p = 0.006). In Cox regression analysis, ANCA was associated with increased mortality, after adjusting for age and sex. ANCA is associated with increased prevalence of ILD and PE in SSc. ANCA should be tested in SSc, as it identifies individuals with worse prognosis who require close monitoring for adverse outcomes.
引用
收藏
页数:12
相关论文
共 29 条
[1]   A case of pulmonary fibrosis associated with rheumatoid arthritis, scleroderma sine scleroderma and ANCA associated vasculitis [J].
Anand, Amritpal Singh ;
Joseph, Priya Brian ;
Vera-Vazquez, Ernest .
SPRINGERPLUS, 2014, 3
[2]   Anti-Neutrophil Antibody Associated Vasculitis in Systemic Sclerosis [J].
Arad, Uri ;
Balbir-Gurman, Alexandra ;
Doenyas-Barak, Keren ;
Amit-Vazina, Mirit ;
Caspi, Dan ;
Elkayam, Ori .
SEMINARS IN ARTHRITIS AND RHEUMATISM, 2011, 41 (02) :223-229
[3]   ANTIMYELOPEROXIDASE ANTIBODIES IN PATIENTS WITH RHEUMATOID-ARTHRITIS - PREVALENCE, CLINICAL CORRELATES, AND IGG SUBCLASS [J].
CAMBRIDGE, G ;
WILLIAMS, M ;
LEAKER, B ;
CORBETT, M ;
SMITH, CR .
ANNALS OF THE RHEUMATIC DISEASES, 1994, 53 (01) :24-29
[4]   Antineutrophil cytoplasmic antibodies in scleroderma patients: first report of a case with anti-proteinase 3 antibodies and review of the literature [J].
Caramaschi, P ;
Biasi, D ;
Tonolli, E ;
Carletto, A ;
Bambara, LM .
JOINT BONE SPINE, 2002, 69 (02) :177-180
[5]  
Casari S, 2002, J RHEUMATOL, V29, P2666
[6]   Antibodies in scleroderma: direct pathogenicity and phenotypic associations. [J].
Chung L. ;
Utz P.J. .
Current Rheumatology Reports, 2004, 6 (2) :156-163
[7]   Revisiting ANCA-associated vasculitis in systemic sclerosis: clinical, serological and immunogenetic factors [J].
Derrett-Smith, Emma C. ;
Nihtyanova, Svetlana I. ;
Harvey, Jennifer ;
Salama, Alan D. ;
Denton, Christopher P. .
RHEUMATOLOGY, 2013, 52 (10) :1824-1831
[8]  
ENDO H, 1994, J RHEUMATOL, V21, P864
[9]  
Hashimoto H., 2010, INT J RHEUMATOL, V2010, DOI DOI 10.1155/2010/148528
[10]   Scleroderma, D-penicillamine treatment, and progressive renal failure associated with positive antimyeloperoxidase antineutrophil cytoplasmic antibodies [J].
Hillis, GS ;
Khan, IH ;
Simpson, JG ;
Rees, AJ .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1997, 30 (02) :279-281